Treatment of intravenously implanted lewis lung carcinoma with liposome-encapsulated cytosine arabinoside and non-specific immunotherapy

✍ Scribed by Kanaiyalal R. Patel; John D. Baldeschwieler

• Book ID: 102866112
• Publisher: John Wiley and Sons
• Year: 1984
• Tongue: French
• Weight: 544 KB
• Volume: 34
• Category: Article
• ISSN: 0020-7136
• DOI: 10.1002/ijc.2910340320

✦ Synopsis

Abstract

Liposomes have been used as biological carriers of anti‐tumor drugs, and their potential use has been tested using various mouse tumors. In this study, we describe a potential role of liposome‐encapsulated 1‐β‐D‐arabinofuranosyl‐cytosine (Ara‐C) with a mouse solid lung tumor model. Non‐encapsulated Ara‐C at 25 mg/kg dose by the intraperitoneal (i.p.) route on days 1, 4 and 7 had no improving effect on the average survival time of tumor‐bearing mice compared to untreated control mice. However, the same dose of Ara‐C encapsulated in multilamellar liposomes (MLV) improved the average survival of tumor‐bearing mice by 60 to 80%. Ara‐C was encapsulated more efficiently when DSPC or DPPC MLV were prepared at temperatures below their respective transition temperatures. DSPC and DPPC MLV prepared at 25°C and DPPC MLV prepared at 50°C were equally effective for in vivo therapy, while DSPC MLV prepared at 60°C were not as effective. Non‐specific immunotherapy using BCG (Bacillus Calmette‐Guérin, Mycobacterium tuberculosis) and CP (Corynebacterium parvum) was effective, particularly when injected by the intravenous (i.v.) route, in prolonging the average survival of tumor‐bearing mice. A combination of either i.v. BCG or i.p. CP with liposome therapy gave no further improvement in the average survival of tumor‐bearing mice. However, a combination of either i.p. BCG od i.v. CP with liposome therapy was somewhat more effective than either liposome therapy or immunotherapy alone.